SYMBIO
1.3.2017 07:02:34 CET | Business Wire | Press release
European hydrogen mobility solutions leader Symbio has revealed a fuel cell integration plan for 5-7 seat Nissan electric vehicles for ultimate freedom at zero emissions to beat air pollution in urban areas, and with hopes to take the vehicle to the European market soon.
At the unveiling of Symbio’s fuel cell integration to Nissan electric van, at the FC Expo 2017 in Tokyo, Japan, the company announced the new plug-in hybrid hydrogen fuel cell vehicle will deliver at least 500 km of range – an important move from Symbio and a promising breakthrough for fleet managers and the automotive community looking for sustainable growth.
Symbio is confident that the FC-equipped vehicle will provide a key solution for emission-free mobility in urban areas. Air pollution is a universal problem and cities some are setting new mandatory regulations to have 20%-50% of their fleets with clean vehicles. In addition, urban taxis have been identified as a major source of air pollution, more emission-related regulations are expected to be applied.
Fabio Ferrari, CEO of Symbio said: “To respect the company’s commitment towards a more sustainable environment and a better air quality in urban areas, we have explored a new market segment - duty vehicles. With this integration to Nissan 5-7 seat EVs, taxis can contribute to the improvement of air quality without any change to their daily activities”
The FC vehicle introduced is a 100% clean solution for taxis, aimed at the EU market. The customised e-NV200 offers taxi drivers a similar total cost of ownership to a hybrid taxi, but with the range of an internal combustion engine. Thus, this vehicle could be used for intensive urban taxi operations or for online passenger transportation network services. It can be recharged from a low-cost power supply, and refuelled with hydrogen in three minutes (3,8 kg Hydrogen).
FC Expo was the opportunity for Symbio to showcase their sustainable mobility solutions to its full, more particularly showing the capacity to produce fuel cells from 5 kW to 300 kW.
Michelin and ENGIE were alongside its partner’s Symbio, to give their support in this new venture and to the hydrogen mobility community overall.
Valérie Bouillon-Delporte, Michelin’s strategic Hydrogen Initiative Leader said “For two years, Michelin has had a 33-percent stake in Symbio. We brought our expertise to the table, as well robust production processes. Michelin is actively involved in the development of fuel-cell technologies and we will continue to invest in this area and in sustainable mobility in general.”
As a global energy supplier, ENGIE has taken steps to speed up the development of clean energies like hydrogen. The Group has invested in Symbio in 2016, to contribute to the evolution of hydrogen uses.
This customised e-NV200 will be available for serial production from September 2018. Interested parties will be able to place pre-orders, by sending a request to Symbio.
“We welcome all interested fleet managers to meet and speak with us on any projects they may have so we can help assist them to move forward” says Fabio Ferrari.
About Symbio
Symbio is the French hydrogen leader offering
innovative sustainable mobility solutions that extend electric vehicle
range and contributes to a low-carbon economy. Symbio designs,
manufactures and sells fuel cell vehicles (Kangoo ZE-H2) and fuel cell
kit systems for integration in all types of vehicles.
QUICK LINKS
Follow us on Twitter - http://bit.ly/Symbio-Twitter
Join
the discussion on LinkedIn - http://bit.ly/Symbio-LidIn
View source version on businesswire.com: http://www.businesswire.com/news/home/20170228006451/en/
Contact:
Communications:
Symbio
Geraldine Hervel
Communications
& Marketing
Email: geraldine.hervel@symbiofcell.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom